Table 5.
Emerging tyrosine kinase inhibitors in metastatic breast cancer

aMotesanib arm vs. bevacizumab arm and motesanib arm vs. placebo arm.
bApproved for use in advanced renal cell carcinoma.
Abbreviations: FGFR, fibroblast growth factor receptor; mPFS, median progression-free survival; mTTP, median time to progression; NS, nonsignificant; ORR, overall/objective response rate; PR; partial response; SD, stable disease.